The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

“We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental ...

A meaningful US access gap persists for off-patent biologics lacking viable biosimilar programs, especially mid-tier products ...

FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...

Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...

In an interview with Pharmaceutical Executive, Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, ...

Lilly’s Foundayo is reportedly off to a strong start. The company’s obesity only recently hit the market, and a report from ...

In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...

However, President Trump posted on his Truth Social account this morning that he is “pleased to announce the new leadership ...

A reverse-merger structure uses Galera’s public listing and cash to bring Obsidian public, while Madan Jagasia is slated to ...